?

Curriculum Vitae

?

NAME: Ni Xie

?

POSITION TITLE: Chief Physician, Researcher, Professor, Doctoral Supervisor

?

EDUCATION/TRAINING

?

A.Personal statement

Ni Xie is a doctor of Oncology and Management, a researcher, a doctoral supervisor and professor,?and has extensive experience researching the molecular mechanisms underlying tumor development, recurrence, metastasis and drug resistance.?At present, she is the Chief of the Science and Education Department and Director of the Biobank of Shenzhen Second People's Hospital, a doctoral supervisor at Guangdong Medical University, and a master’s supervisor at Shenzhen University, Guangzhou Medical University and Nanhua University.?

Dr. Xie is also a member of the Information Group and of the Professional Committee of Clinical Data and Sample Resource Base of the China Research Hospital Association, a member of the Standing Committee of the Special Committee of Viral Oncology of the China Research Hospital Association, a member of the Tumor Marker Committee of the China Anti-Cancer Association. She is also a standing member of the Precision Medicine and Molecular Diagnostics Branch of Guangdong Medical Association, and of the Professional Committee of Integration of Chinese and Western Medicine of Guangdong Academy of Traditional Chinese Medicine. She is a Guangdong Provincial Natural Science Foundation peer review expert, Shenzhen Science and Technology review expert. Furthermore, she is the director of the Shenzhen Immune Cell Therapy Engineering Laboratory and the deputy director of Shenzhen Key Laboratory of Nanoenzyme Oncology.

She currently serves as an editorial board member of "Cancer Management and Research" and "International Journal of Oncology". She has published more than 40 high-quality academic papers in international journals, including in?Nature Communications and?Theranostics, and has obtained 6 national invention patents. She has presided over more than 20 national, provincial and municipal projects and, in the past five years alone, she has received more than 20 million yuan in project funding. She also trained 15 postgraduates, won the second-place Science and Technology Prize of the Chinese Society of Integrated Chinese and Western Medicine, and won the Guangdong Science and Technology Progress Award.

?

B. Positions and honors

Positions

2004-present: ?Chief Physician, Researcher, Professor and Doctoral Supervisor;?Shenzhen Second?People’s Hospital (First Affiliated Hospital of Shenzhen University), Shenzhen, China

1997-2001: ?Teaching Assistant and Research Assistant;?Department of Microbiology, Xiangya Medical College, Central South University, Changsha, China

?

Honors

1.2019: Award for Science and Technology of Chinese Society of Integrated Traditional Chinese and Western Medicine (2^nd position).

2.2016: Award for Guangdong Science and Technology (2^nd position)

3.2014: Award for Guangdong Science and Technology?(2^nd position)

?

C. Representative publications (selected publications in recent five years ? 5-10篇)

1.Xiaolong Tang#, Lei Shi#, Ni Xie#, Zuojun Liu Minxian Qian, Fanbiao Meng, Qingyang Xu, Mingyan Zhou, Xinyue Cao, Wei-Guo Zhu, Baohua Liu. SIRT7 Antagonizes TGF-β Signaling and Inhibits Breast?Cancer Metastasis, Nature Communications. 2017, 8(1):318.（IF 12.353）

2.Bingjie Liu#, Ruikai Du#, Lei Zhou, Jiahui Xu, Song Chen, Ji Chen, Xiaoli Yang, Dong-xu Liu, Zhi-ming Shao, Lixing Zhang, Zuoren Yu, Ni Xie*, Jun-lin Guan*, and Suling Liu*. miR-200c/141 Regulates Breast Cancer Stem Cell Heterogeneity via Targeting HIPK1/β-Catenin Axis. Theranostics. 2018, 8(21): 5801-5813.（IF 8.063）

3.Lei Zhou#, Dong Wang#, Dandan Sheng#, Jiahui Xu, Weilong Chen, Yuanyuan Qin, Ruikai Du, Xiaoli Yang, Xueyan He, Ni Xie*, Suling Liu*, Lixing Zhang*. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer. Theranostics. 2020, 10(5): 2405-2421. (IF 8.063)

4.Fan Yang, Siqi Chen, Shengnan He, Qin Huo, Ye Hu and Ni Xie*. YB-1 interplays with ERα to regulate the stemness and differentiation of ER-positive breast cancer stem cells. Theranostics. 2020, 10(8): 3816-3832. (IF 8.063)

5.Pranav Gupta, Yun-Kai Zhang, Xiao-Yu Zhang, Yi-Jun Wang, Kimberly W. Lu, Timothy Hall, Richard Peng, Dong-Hua Yang, Ni Xie*, Zhe-Sheng Chen*. Voruciclib, a Potent CDK4/6 Inhibitor, Antagonizes ABCB1 and ABCG2- Mediated Multi-Drug Resistance in Cancer Cells. Cellular Physiology and Biochemistry. 2018, 45(4): 1515-1528.（IF 5.500）

6.Qin Huo，Zhenwei Li，Lixin Cheng, Fan Yang, Ni Xie*. SIRT7 is a prognostic biomarker associated with immune infiltration in luminal breast cancer. Front. Oncol. 2020, 10(621): doi: 10.3389/fonc.2020.00621. (IF 4.137)

7.Ni Xie, Zhonghang Li, Ran Zuo, Suwen Qi, Ting Zhu, Litao Liu, Lili Wan, Jianhui Yuan. Serum SAA1 and APOE are novel indicators for human cytomegalovirus infection. Sci Rep. 2017, 7(1):13407.（IF 4.122）

8.Gong Zhang, Tian Guan, Zhiyuan Shen, Xiang Wang, Tao Hu, Dawei Wang, Yonghong He*, Ni Xie*. Fast phase retrieval in off-axis digital holographic microscopy through deep learning. Optics Express, 2018, 26(15):19388-19405. (IF 3.561)

9.Suwen Qi, Si Huang, Xin Chen, Qin Huo, Ni Xie*, Jun Xia, Liver tissue metabolic profiling and pathways of non-alcoholic steatohepatitis in rats, Hepatology Research. 2017, 47(13): 1484-1493.（IF 3.415）

10.Yongsheng Su, Jian Hu, Zhhibin Huang, Bingsheng Peng, Ni Xie*, Hui Liu*, Paclitaxel-loaded star-shaped copolymer nanoparticles for enhanced malignant melanoma chemotherapy against multidrug resistance, Drug Design Development & Therapy. 2017, 11:659-668.（IF 2.935）

?

D. Research support

Ongoing projects (RMB)

1.??National Natural Science Foundation of China.?SIRT7 as a new diagnostic marker of breast cancer metastasis and its mechanism of interaction with positive feedback of chromosomal instability. (Grant no. 81972003, 2020-2023，￥550,000). Project leader:?Ni Xie.

2. ?Basic Research of Science and Technology Innovation Committee of Shenzhen Municipality (discipline layout). Study on signal pathway and drug target of drug resistant breast cancer stem cells. (Grant no. JCYJ20170818085657917, 2018-2020，￥2,000,000). Project leader: Ni Xie.

3. ?Basic Research of Shenzhen Knowledge Innovation Plan?(discipline layout). Study on the detection technology of high sensitive multi-target immunoassay strip. (Grant no. JCYJ20170817171808368,?2018/01-2020/12, ￥2,000,000). Project leader: Ni Xie.

4. ?Natural Science Foundation of Guangdong Province. Hypoxia Induced URG11 Gene In The Metastasis Of Triple-negative Breast Cancer And Its Molecular Mechanism. (Grant no. 2017A303013668, 2017/05-2020/05, ￥100,000). Project leader: Ni Xie.

5. Natural Science Foundation of Guangdong Province. Regulatory effect and mechanism of siRNA targeting BCRP / ABCG2 in breast cancer cells. (Grant no. 2016A030313029, 2016/06-2019/06，￥100,000). Project leader: Ni Xie.

6. ?International Cooperation Project of Shenzhen Collaborative Innovation Program. The molecular mechanism of hypoxia-induced URG11 gene expression and its role in targeted therapy of Triple-negative Breast Cancer. (Grant no. GJHZ20160301163138685, 2016/06-2018/12，￥500,000). Project leader: Ni Xie.

7. ?Basic Research Project of Shenzhen Knowledge Innovation Program. Experimental study of magnetic siRNA-CCMN targeted regulation of breast cancer cell resistance protein gene BCRP/ABCG2. (Grant no. JCYJ20150330102720122, 2015/08-2017/07，￥300,000). Project leader: Ni Xie.

8. ?Guangdong Science and Technology Plan Project. Study on the expression and mechanism of HIF-1 and survivin in breast cancer EGFR pathway. (Grant no. 2014A020212038, 2014/10-2017/02，￥100,000). Project leader: Ni Xie.

9. ?Guangdong Science and Technology Plan Project.?Study on chemotherapy effect of adriamycin loaded nano targeting "Triple-negative" breast cancer. (Grant no. 2013B021800097, 2014/01-2015/12，￥50,000). Project leader: Ni Xie.

10. International Cooperation Project of Shenzhen Technology Innovation Program. Doxorubicin-containing nano-targeted "Triple-negative" breast cancer chemotherapy efficacy and reversal of drug tolerance. (Grant no. GJHZ20130412153906740, 2013/09-2015/09，￥300,000). Project leader: Ni Xie.

11. Basic Research Project of Shenzhen Technology Research Program. Application of pharmacogenomics in the individualized use of antitumor drugs. (Grant no. JCYJ20120613171430264, 2012/6-2015/6，￥1,000,000). Project leader: Ni Xie.

12. National Natural Science Foundation Youth Fund Project. Experimental study of reverse viral vector-mediated RNAi to reverse BCRP drug tolerance. (Grant no. 30500599, 2006/01-2008/12，￥250,000). Project leader: Ni Xie.

13. National Natural Science Foundation Youth Fund Project.?Study on the mechanism of developmental malformation of fetal central nervous system caused by HCMV. (Grant no. 304700188, 2004/01-2007/12，￥20,0000). Project leader: Ni Xie.

?